Columbia Asset Management raised its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 57,358 shares of the company’s stock after buying an additional 832 shares during the quarter. Johnson & Johnson makes up approximately 2.5% of Columbia Asset Management’s portfolio, making the stock its 7th biggest holding. Columbia Asset Management’s holdings in Johnson & Johnson were worth $10,132,000 at the end of the most recent quarter.
A number of other hedge funds also recently added to or reduced their stakes in JNJ. Glassy Mountain Advisors Inc. purchased a new position in Johnson & Johnson in the fourth quarter valued at about $35,000. Retirement Financial Solutions LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at about $40,000. TD Capital Management LLC purchased a new position in Johnson & Johnson in the third quarter valued at about $48,000. VitalStone Financial LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $52,000. Finally, Iron Horse Wealth Management LLC grew its position in shares of Johnson & Johnson by 112.8% in the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after purchasing an additional 159 shares during the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Johnson & Johnson
In related news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.20% of the company’s stock.
Johnson & Johnson Stock Down 1.4 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating the consensus estimate of $2.51 by $0.17. The business had revenue of $24.75 billion for the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The business’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.67 EPS. Analysts forecast that Johnson & Johnson will post 10.66 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. This represents a $4.76 annualized dividend and a dividend yield of 3.08%. Johnson & Johnson’s payout ratio is presently 99.58%.
Wall Street Analyst Weigh In
Several analysts have recently commented on the stock. Morgan Stanley increased their price target on shares of Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 19th. Guggenheim assumed coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target on the stock. StockNews.com started coverage on shares of Johnson & Johnson in a research report on Thursday, May 18th. They issued a “strong-buy” rating on the stock. UBS Group started coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 target price on the stock. Finally, Piper Sandler decreased their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $173.00.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.